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Summary
Heparin-induced thrombocytopenia (HIT) is an immune-
mediated adverse drug effect that occurs in 0.1–5% of he-
parin treated patients. Management of acute HIT currently
involves (1) cessation of heparin exposure, and (2) inhi-
bition of coagulation with an anticoagulant other than he-
parin. Several anticoagulants can be considered for the
treatment of HIT. Anticoagulant monitoring, management
of drug-induced adverse events including bleeding, and
therapeutic dosing schedules in selected clinical settings
represent challenges to the clinician treating HIT patients.
Moreover, the fact that not all registered anticoagulants
are approved for HIT in Switzerland further complicates
the management of HIT. The present recommendations
on the anticoagulant treatment of HIT in Switzerland have
been elaborated by a panel of Swiss experts belonging to
the Working Party Hemostasis (WPH) of the Swiss Soci-
ety of Hematology (SGH-SSH). They are intended to sup-
port clinicians in their decision making when treating HIT
patients.
Keywords: anticoagulation, argatroban, bivalirudin, dana-
paroid, fondaparinux, heparin, heparin-induced thrombo-
cytopenia, HIT, direct oral anticoagulants, rivaroxaban
Introduction
Heparin-induced thrombocytopenia (HIT) is an immune-
mediated severe adverse drug effect that occurs in 0.1–5%
of heparin-treated patients. HIT is defined by the concomi-
tant presence of acquired thrombocytopenia (platelet count
below 100 G/l or a relative drop of ≥30%) and HIT anti-
bodies (HIT-Abs). HIT-Abs are immunoglobulin G (IgG)
antibodies directed against a multimeric complex of a pa-
tient’s chemokine, most often platelet factor 4 (PF4), and
the drug, heparin or other polyanionic macromolecules.
Not all HIT-Abs induce thrombocytopenia. Only the so-
called functional HIT-Abs lead to thrombocytopenia and
the subsequent generation of thrombin. Thrombocytopenia
in HIT, caused by platelet consumption, is typically mod-
erate (platelet count around 60 G/l). Hypercoagulability is
caused by platelet, monocyte, neutrophil and endothelial
cell activation, resulting in concomitant activation of coag-
ulation. As both platelets and coagulation become activat-
ed in HIT, the resulting hypercoagulable state affects both
the venous and the arterial vascular beds [1, 2].
HIT diagnosis requires assessment of pretest probability
utilising a validated score. Based on the result of the score,
and the result of a quantitative HIT-Abs immunoassay,
post-test probabilities are determined, permitting HIT di-
agnosis. The HIT-Abs enzyme-linked immunosorbent as-
say (ELISA) tests are usually highly sensitive, but not very
specific, diagnostic tests. There are differences between
immunoassays for HIT, and only some of them have at
the same time high sensitivity and high specificity [3].
Imperfect specificity makes it necessary that positive im-
munoassay results are confirmed by functional tests, such
as heparin-induced platelet aggregation or serotonin re-
lease assays. Recent publications [4–6] have demonstrated
that the Bayesian combination of pretest clinical likelihood
with the magnitude of an immunoassay for HIT-Abs can
predict the outcome of the functional assay, so that addi-
tional confirmatory platelet-activation assays may become
unnecessary, for example for patients with high pretest
clinical probability and high HIT-Abs titres [7].
Evidence-based management of acute HIT currently in-
volves two main aspects: cessation of heparin exposure
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and inhibition of coagulation with an anticoagulant other
than heparin. Recently, the use of high-dose intravenous
immunoglobulin has been reported to rapidly inhibit HIT-
Abs-induced platelet activation [8, 9]. This therapeutic ap-
proach might constitute an important adjunct treatment to
anticoagulation in patients with HIT [8, 9]. Efficient treat-
ment of HIT will lead to the normalisation of the platelet
count (typically within 5–7 days) and prompt mitigation of
the hypercoagulable state [10, 11].
The aim of this article is confined to the appropriate use of
anticoagulants and does not include general management
of HIT. Several drugs can be considered for the anticoagu-
lant treatment of HIT. Anticoagulant monitoring, manage-
ment of drug-induced adverse events particularly bleeding,
and dosing schedules in the presence of renal or hepatic
dysfunction and other selected clinical situations represent
challenges to the clinician treating HIT patients. Moreover,
the fact that not all registered anticoagulants are approved
for HIT in Switzerland further complicates the manage-
ment of HIT. Lepirudin, licensed for HIT treatment, was
withdrawn from the market worldwide.
Once the acute phase of HIT has been successfully treated,
transitioning of parenteral anticoagulant treatment to a di-
rect oral anticoagulant (DOAC) or a vitamin K antagonist
(VKA) can be considered. DOACs are preferred over
VKAs for stable patients with an average bleeding risk af-
ter platelet count recovery [12, 13]. Prerequisite for tran-
sitioning to oral anticoagulant is the normalisation of the
platelet count (platelet count ≥150 G/l [14]) / return of the
platelet count to the level before the HIT episode. VKA
treatment should be started only when both of criteria are
met. These precautionary measures aim to minimise the
risk of coumarin-associated microthrombosis syndromes
(venous limb gangrene, skin necrosis). Alternative anti-
coagulation can be stopped once two subsequent interna-
tional normalised ratio (INR) measurements, performed at
least 24 hours apart, are in the therapeutic range. Admin-
istration of low doses of a VKA without a loading dose is
recommended.
The Working Party Hemostasis (WPH) of the Swiss Soci-
ety of Hematology proposes a guideline for the treatment
of HIT based on current available evidence, international
guidelines and consensus expert opinion. The paper pre-
sents all available treatment modalities in Switzerland, al-
lowing direct implementation. Multiple rather than single
recommendations are presented, allowing a tailored strate-
gy according to physicians’ preferences and experience. It
is in the context of a complex disease with relevant treat-
ment risks, associated with potentially high treatment costs
and limited resources, that the WPH has prepared a guide-
line for the treatment of HIT in Switzerland. In addition to
other current guidelines, including those of the American
Society of Hematology 2018 [12], we provide information
on dosing schedules of anticoagulants for HIT patients in
different clinical conditions.
The pharmacokinetic/pharmacodynamics properties of all
anticoagulants in use for HIT treatment are summarised in
table 1 and discussed in alphabetical order.
Argatroban (Argatra®)
Regulatory status
Swissmedic
– Anticoagulation in adult patients with HIT requiring a
parenteral antithrombotic therapy.
– HIT diagnosis has to be confirmed by a heparin-in-
duced platelet activation assay (HIPA) or an equivalent
test. However, this confirmation should not delay the
initiation of treatment [15].
US Food and Drug Administration (FDA)
− Prophylaxis or treatment of thrombosis in adult patients
with HIT, and as an anticoagulant in adult patients with or
at risk of HIT undergoing percutaneous coronary interven-
tion (PCI) [16].
Pharmacokinetics/pharmacodynamics
Molecule: Argatroban is a small (molecular weight 527
Daltons), direct, selective and reversible inhibitor of the
thrombin active site, which is synthetically derived from
L-arginine (structurally unrelated to heparin) [17]. Arga-
troban inhibits all thrombin-catalysed steps in the coagula-
tion system (fibrin formation, activation of factors V, VIII,
and XIII, and of protein C, and thrombin-induced platelet
aggregation). It is not inactivated by PF4 and does not
cross-react with heparin-induced antibodies. Argatroban
does not require antithrombin for its anticoagulant activity
(hence “direct”).
Distribution: Predominantly in the extracellular fluid;
20–54% is reversibly bound to human serum proteins [18].
Table 1: Properties of anticoagulants used for the treatment of heparin-induced thrombocytopenia.
Argatroban
(Argatra®)
Bivalirudin
(Angiox®)
Danaparoid
(Orgaran®)
Fondaparinux
(Arixtra®)
Rivaroxaban*
(Xarelto®)
Mode of action Anti-factor IIa (thrombin) Anti-factor IIa (thrombin) Anti-factor Xa
AT-mediated
Anti-factor Xa
AT-mediated
Anti-factor Xa
Route of application i.v. i.v. i.v./s.c. s.c. p.o.
Predominant clearance Hepatobiliary Proteolytic inactivation
(80%) and renal (20%)
Renal Renal Hepatobiliary (67%), renal
(33%)
Elimination half-life 40–50 minutes 25 minutes 19–25 hours 17–21 hours 7–11 hours
Hepatic metabolism Yes No No No Yes
Monitoring preference Anti-factor IIa assay
(± aPTT)
Anti-factor IIa assay
(± aPTT)
Anti-factor Xa assay Anti-factor Xa assay† Anti-factor Xa assay†
Significant influence on routine
coagulation tests
Yes Yes None None Yes
aPTT = activated partial thromboplastin time; AT = antithrombin; i.v. = intravenous; s.c. = subcutaneous; p.o. = per os * Limited available data supporting the use of rivaroxaban
in HIT, for details see text † Monitoring is not generally required but may be recommended in special situations, such renal insufficiency
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Metabolism: Hepatic.
Excretion: Hepatobiliary clearance.
Half-life: 40–50 minutes.
How to use the drug in patients with HIT
The WPH recommends the use of argatroban as a continu-
ous intravenous infusion (table 2), with an initial bolus on-
ly in a restricted number of specific indications (table 3).
In the absence of organ failure, the dose recommended in
the manufacturer’s prescribing information is 2 μg/kg/min.
However, several publications indicate that this dose is too
high and that an initial dose of 1 μg/kg/min is adequate for
patients without organ function impairment [22, 29, 30].
In critically ill patients with cardiac failure or other organ
dysfunctions, it is suggested to begin with an even lower
dose (0.5 μg/kg/min or less). Indeed, there may be a four-
fold clearance decrease of the drug, especially when hepat-
ic impairment is present. In patients with moderate hepatic
dysfunction (bilirubin >25.5 μmol/l, alanine aminotrans-
ferase [ALAT] >3 times the upper limit of the reference
range) a starting dose of 0.25 μg/kg/min is suggested [31].
Table 2 summarises the recommended dosing schedules of
argatroban [23, 24].
How to use argatroban in HIT subpopulations
Renal insufficiency: No dosage adjustment is necessary in
patients with renal insufficiency. Clearance of argatroban
by high-flux membranes is considered clinically insignif-
icant (approximately 20% of the drug is cleared through
dialysis) [32, 33].
Liver insufficiency: Liver insufficiency is associated with
decreased clearance and an increased elimination half-life
of argatroban. Argatroban is contraindicated in severe liver
insufficiency [33].
Pregnancy: Administer during pregnancy only if absolute-
ly necessary and if no alternative exists. It is not known
whether the drug is excreted into breast milk [15, 34–36].
Geriatrics: The effectivity of argatroban does not seem to
be affected by age [33]. However, there are insufficient da-
ta to determine if its absorption, distribution and elimina-
tion are different in elderly patients (≥65 years).
Paediatrics: Limited evidence is available. Dose recom-
mendations are found in the Swiss compendium [15]. Ar-
gatroban clearance is decreased in seriously ill paediatric
patients.
Monitoring
Argatroban monitoring is detailed in table 4. Target ranges
for the various tests used have not been established in
an outcome-based setting. Argatroban increases thrombin-
based coagulation times (prothrombin time [PT] and the
PT-derived international normalised ratio [INR] expres-
sion; activated partial thromboplastin time (aPTT); throm-
bin time (TT); activated clotting time [ACT]) in a con-
centration-dependent manner. Daily anti-factor IIa testing
(by a commercially calibrated diluted TT) is the preferred
monitoring modality, followed by aPTT monitoring. Anti-
factor IIa and/or aPTT monitoring is scheduled before and
2 hours after the start of the argatroban infusion (steady-
state levels of drug and anticoagulant effect are expected
after five half-lives), 2 hours after each dose adjustment
and then daily. The proposed target argatroban concen-
tration is 0.4–1.5 μg/ml [22, 25]. The aPTT is aimed at
1.5−3.0 times the patient’s baseline (provided baseline
aPTT was within the reference range) without exceeding
100 sec with most reagents; the precise target range de-
pends very much on the local reagent/coagulometer com-
bination and has to be established in-house. Importantly,
there is a flattening of the concentration response relation-
ship, so that over-anticoagulation is difficult to detect [37,
38].
Of note, determination of the fibrinogen concentration can
be affected by the administration of argatroban. Depending
on the assay employed, argatroban may cause an under-
estimation of the fibrinogen concentration, particularly at
supra-therapeutic argatroban plasma levels [39, 40].
Conversion to oral anticoagulant therapy with vitamin
K antagonists
Co-administration of a VKA and argatroban has a com-
bined effect on INR, prolonging INR beyond the value pro-
duced by a VKA alone. The INR should be measured daily
while argatroban and VKA are co-administered. The tran-
sition is considered moderately complicated and the initial
target INR has to be set to at least 4; after two INR values
in the desired therapeutic range 24 hours apart, argatroban
can be stopped; the INR has to be reassessed 4–6 hours lat-
er [15, 41, 42], now targeting an INR of 2–3. See also the
Introduction section regarding conditions necessary prior
to transitioning to VKA, and figure 1.
Safety
Specific contraindications
– Severe liver insufficiency.
Caution
Caution is recommended in:
Table 2: Initial dose of argatroban in various clinical situations.
Situation Initial dose
Acute HIT (with or without thromboembolism) 1.0 µg/kg/min (standard dose)
Acute HIT with life-threatening thromboembolism 2.0 µg/kg/min (monitoring in intensive care mandatory)
Critically ill patients 0.5 µg/kg/min or other doses according to the nomogram (table 3)
Moderate liver insufficiency 0.25 µg/kg/min
Severe liver insufficiency Argatroban contraindicated
(prescribe fondaparinux or bivalirudin instead)
Children with normal liver function 0.75 µg/kg/min
Children with reduced liver function 0.25 µg/kg/min
HIT = heparin-induced thrombocytopenia
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Table 3: Dosing schedules of anticoagulants in patients with heparin-induced thrombocytopenia.
Indication Anticoagulant
Argatroban Bivalirudin Danaparoid Fondaparinux DOACs*
Prevention of VTE in pa-
tients with a history of HIT
Bolus: No
Injection:
750 U s.c. 2–3 ×/d [19, 20]
Bolus: No
Injection:
2.5 mg s.c. 1 ×/d [21]
Rivaroxaban: 1 × 10 mg/d orally
Apixaban: 2 × 2.5 mg/d [15]
Acute HIT
(with or without VTE)
Bolus: No
Continuous infusion:
0.5–1 µg/kg/min (max.
10 µg/kg/min)
Adjust to aPTT of
1.5–3.0 × patient
baseline and/or TT
(in-house target)
Adjust to anti-factor
IIa activity of 0.4–1.0
(max 1.5) µg/ml
[22–25]
Bolus: No
Continuous infusion:
Cr Cl >60ml/min 0.06 mg/kg/h
Cr Cl 30−60ml/min 0.04 mg/
kg/h
Cr Cl 15−30ml/min 0.02 mg/
kg/h
Cr Cl <15ml/min contraindicat-
ed†
Adjust to aPTT of 1.5–2.5 ×
patient baseline
Adjust to anti-factor IIa activity
of 1.0 µg/ml, range 0.5–1.5 µg/
ml‡
Dose reduction in cases of re-
nal or hepatic dysfunction as
described above or according
to literature [26, 27]
i.v. schedule
Bolus:
<60 kg: 1500 U
60–75 kg: 2250 U
75–90 kg: 3000 U
>90 kg: 3750 U
Continuous infusion:
400 U/h for 4 h followed
by 300 U/h for 4 h fol-
lowed by 150–200 U/h de-
pending on the renal func-
tion
Adjust to anti-factor Xa
activity 0.5–0.8 IU/ml [19,
20]
s.c. schedule
Low dose scheme:
i.v. loading dose of 750 U
(≤90 kg) or 1250 U (>90
kg), followed by
750 U 3 ×/d (≤90 kg) or
1250 U 3 ×/d (>90 kg) s.c.
High dose scheme: i.v.
loading dose of 2000 U
followed by 2000 U 2 ×/d
s.c.
1500–2250 U i.v. 2 ×/d
(i.v. schedule during the
acute phase of HIT)
Adjust to anti-factor Xa
activity 0.5–0.8 U/ml [19,
20]
s.c. schedule (daily)
Bolus: No
Injection:
≥50 ≤100 kg: 7.5 mg
<50 kg: 5 mg
>100kg: 10 mg
Creatinine clearance
30–50 ml/min: use with
caution
Creatinine clearance
<30 ml/min: contraindi-
cated [21, 28]
Treatment of ATE Bolus: No
Continuous infusion:
0.5−1 µg/kg/min (max.
10 µg/kg/min)
Adjust to aPTT of
1.5−3.0 × patient
baseline
Adjust to anti-factor
IIa activity of 0.4−1.5
µg/ml [23, 24]
Bolus: No
Continuous infusion:
See above
Adjust to aPTT of 1.5−2.5 ×
patient baseline
Adjust to anti-factor IIa activity
of 1.0 µg/ml, range 0.5−1.5 µg/
ml‡
Dose reduction in the case of
renal or hepatic dysfunction
[26, 27]
i.v. schedule
Bolus:
<60 kg: 1500 U
60−75 kg: 2250 U
75−90 kg: 3000 U
>90 kg: 3750 U
Continuous infusion:
400 U/h for 4 h followed
by
300 U/h for 4 h followed
by
150−200 U/h
Adjust to anti-factor Xa
activity of 0.5−0.8 U/ml
[19, 20, 49]
s.c. schedule
Bolus: No
Injection:
1500−2250 U s.c. 2 × dai-
ly (i.v. during the acute
phase of HIT)
Adjust to anti-factor Xa
activity of 0.5−0.8 U/ml
[19, 20, 49]
Bolus: Optional (i.v.)
Injection: 2.5 mg/d s.c.
[21]
−
Treatment of unstable
angina / MI
− Bolus: No
Continuous infusion:
see above
Adjust to aPTT 1.5−2.5 × pa-
tient baseline
Adjust to anti-factor IIa activity
of 1.0 µg/l, range 0.5−1.5 µg/
ml‡
Dose reduction in the case of
renal or hepatic dysfunction
[47]
− Bolus: Optional (i.v.)
Injection:
2.5 mg/d s.c. [15]
−
Stroke prevention and
prophylaxis of systemic
embolism in non-valvular
atrial fibrillation
− − − − DOACs according to labelling [15]
Catheter patency − − 750 U in 50 ml NaCl
0.9%; 5−10 ml/catheter or
more when necessary [74]
− −
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Indication Anticoagulant
Argatroban Bivalirudin Danaparoid Fondaparinux DOACs*
Intermittent haemodialy-
sis (alternating days)
Bolus: Optional
250 µg/kg i.v.
Continuous infusion:
2 µg/kg/min i.v.
If no bolus, start con-
tinuous infusion 4 h
before dialysis
Adjust to aPTT of
1.5−3.0 patient base-
line
Adjust to anti-factor
IIa activity of 0.4−1.5
µg/ml [32]
− Bolus: No
Injection: 3750 U (2250 U
if weight <55 kg) i.v. prior
to 1st and 2nd dialyses,
3000 U (2000 U if weight
<55 kg) i.v. prior to 3rd
dialysis
For subsequent dialyses,
adjust according to pre-
dialysis anti-factor Xa:
If anti-factor Xa activity
<0.3 U/ml, give 3000 U i.v.
Adjust to anti-factor Xa
during dialysis: 0.5−0.8 U/
ml [15, 74]
− −
Continuous renal re-
placement therapy
Bolus: No
Continuous infusion:
0.5−1 µg/kg/min de-
pending on liver func-
tion
Adjust to aPTT of
1.5−3.0 × patient
baseline
Adjust to anti-IIa activ-
ity of 0.4−1.5 µg/ml
[75, 76]
Bolus: No
Continuous infusion:
0.006−0.04 mg/kg/h
Adjust to aPTT of 1.5−2.5 ×
patient baseline [26]
Adjust to anti-factor IIa activity
of 1.0 µg/ml, range 0.5−1.5 µg/
ml‡
Bolus: 2250 U i.v.
Continuous infusion:
400 U/h for 4 h (600 U/h
max.) followed by
300 U/h for 4 h, followed
by
150−400 U/h aiming for
anti-factor Xa activity
0.5−0.8 IU/ml [74]
− −
Peripheral vascular
surgery
Bolus:
350 µg/kg (in 3−5
min)
Continuous infusion:
25 µg/kg/min
Adjust continuous in-
fusion dose to ACT
300−500 sec,
checked 5−10 min af-
ter the initial bolus.
If necessary, addition-
al bolus of 150 µg/kg
[77]
− Preoperative
Bolus:
<60 kg: 1500 U
60−75 kg: 2250 U
75−90 kg: 3000 U
>90 kg: 3750 U
Peroperative rinsing:
750 U in 250 ml NaCl
0.9%, using up to 50 ml
Postoperative (≥ 6 h after
surgery)
Low risk patients: 750 U 3
× day s.c.
High risk patients:
150−200 U/h i.v. [74]
− −
PCI Bolus:
350 µg/kg (in 3−5
min) without GP IIb/II-
Ia inhibitor
250−350 µg/kg with
GP IIb/IIIa inhibitor
Continuous infusion:
25 µg/kg/min without
GP IIb/IIIa inhibitor
15 µg/kg/min with GP
IIb/IIIa inhibitor
Adjust continuous in-
fusion dose to ACT
300−500 sec,
checked 5−10 min af-
ter the initial bolus.
If necessary, addition-
al bolus of 150 µg/kg
Removal arterial intro-
ducer:
≥2 h after drug inter-
ruption and check for
ACT 160 sec [78, 79]
Bolus:
0.75 mg/kg aiming for ACT
>225 sec; second bolus op-
tional (0.3 mg/kg)
Continuous infusion:
1.75 mg/kg/h during PCI, max
4 h
Adjust infusion to 1.4 mg/kg/
min if creatinine clearance is
30-59 ml/min
Contraindicated if creatinine
clearance is <30 ml/min
Removal arterial introducer ≥2
h after perfusion arrest [15]
Preprocedure
Bolus:
<60 kg: 1500 U
60−75 kg: 2250 U
75−90 kg: 3000 U
>90 kg: 3750 U
Postprocedure
Continuous infusion:
150−200 U/h for 1−2 days
Adjust to anti-factor Xa
activity of 0.5−0.8 U/ml
[74]
− −
Intra-aortic balloon pump Bolus: No
Continuous infusion:
0.5−1 µg/kg/min de-
pending on liver func-
tion
Adjust to aPTT
1.5−3.0 × patient
baseline <100 sec
Adjust to anti-factor
IIa activity of 0.4−1.5
µg/ml [80]
− Preprocedure
Bolus:
<60 kg: 1500 U
60−75 kg: 2250 U
75−90 kg: 3000 U
>90 kg: 3750 U
Postprocedure
Continuous infusion:
150−200 U/h i.v. until re-
moval of balloon pump
Adjust to anti-factor Xa
activity of 0.5−0.8 U/ml
[74]
− −
Extracorporeal mem-
brane oxygenation
Bolus: No
Continuous infusion:
0.2 µg/kg/min
− Bolus: No
Continuous infusion: 400
U/h
− −
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– Patients with increased risk of bleeding, such as patients
with severe hypertension, inherited or acquired bleed-
ing disorders, gastrointestinal lesions, or immediately
following lumbar puncture, spinal anaesthesia or major
surgery.
– Patients with any other form of anticoagulation or with
antiplatelet therapy.
– Patients with impaired liver function, because of the de-
creased metabolism of argatroban and prolonged half-
life requiring a reduction of the infusion rate.
– Patients with a significant third space, because of the
accumulation of argatroban and prolonged half-life af-
ter discontinuation.
– Patients with elevated baseline aPTT; in these patients
it is especially important to monitor argatroban using
drug level (commercially calibrated diluted TT, for ex-
ample) rather than using the aPTT [43].
Antidote
No specific antidote to argatroban is available. However,
argatroban’s relatively short half-life reduces the need for
an antidote agent.
Management of bleeding
No specific recommendations are defined. Coagulation pa-
rameters typically return to baseline within 2–4 hours after
discontinuation of the drug (short half-life in the absence
of hepatic dysfunction and third space). Symptomatic and
Indication Anticoagulant
Argatroban Bivalirudin Danaparoid Fondaparinux DOACs*
Adjust to aPTT 50−60
sec
Adjust to anti-factor
IIa activity 0.4−1.5 µg/
ml [81]
Adjust to anti-Xa activity
0.6−0.8 U/ml (monitoring
2× daily) [82]
Off-pump coronary
artery bypass
− Bolus: 0.75 mg/kg
Continuous infusion:
1.75 mg/kg/h aiming for ACT
>300 sec (stop infusion ap-
prox. 20 min before end of
grafting)
Increase of perfusion rate by
0.25 mg/kg/h when ACT <300
sec [83–85].
− − −
CPB − Bolus: 1 mg/kg
Continuous perfusion: 2.5 mg/
kg/h
In pump circuit: 50 mg
Adjust to ACT 2.5 × patient
baseline
If ACT <2.5 patient baseline:
bolus 0.25 mg/kg and increase
of perfusion of 0.25 mg/kg/h
Stop infusion approx. 15 min
before end of CPB
Extracorporeal elimination: en-
hanced by the use of modified
haemofiltration (Minntech He-
mocor HPH 700 membrane)
Management of circuit after
CPB: bolus of 50 mg followed
by a continuous infusion of 50
mg/h. Process blood with a
cell saver before reinfusion to
avoid overdosage.
Cell saver: contains sodium
citrate [48, 86, 87]
− − −
ACT = activated clotting time; ATE = arterial thromboembolism; CBP = cardiopulmonary bypass; d = day; GP = glycoprotein; HIT = heparin-induced thrombocytopenia; h = hour;
i.v. = intravenous; IU = international unit; MI = myocardial infarction; min = minute; PCI = percutaneous coronary intervention; s.c. = subcutaneous; sec = second; U = unit; VTE =
venous thromboembolism * Note: prophylaxis only as authorised by Swissmedic (major orthopaedic surgery). Currently there are not enough data supporting the use of direct oral
anticoagulents as a first line therapy in HIT. † Depending on the type of renal replacement system (hemofiltration/haemodialysis) utilised, bivalirudin can be used in the context of
severe renal insufficiency. ‡ The target has to be evaluated in the routine laboratory with the local reagents/coagulometer combination.
Table 4: Argatroban monitoring with aPTT and/or anti-IIa activity.
aPTT*
(sec.)
Argatroban dose Next check†
(h)
Anti-IIa activity
(µg/ml)
<35 +20% 2 <0.3
35−45‡ +10% 2 0.3−0.4‡
46−70 No change 4−12;
(in steady-state: 12−24 h)
0.4−1.5
71−90 −10% 2 >1.5
>90 −20% and
Stop for 1−2 h
2
aPTT = activated partial thromboplastin time; anti-IIa activity = anti-activated factor II (or thrombin) activity * Aim: 1.5 to 3.0 × patient baseline aPTT, the given aPTT values are
valid only if the patient baseline aPTT is within the normal range; † daily anti-IIa activity in addition to aPTT and, as well as daily kidney and liver function tests; ‡ prophylactic
dose: aPTT 35−45 sec., Anti-IIa activity argatroban: 0.3-0.4 µg/ml.
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supportive therapy, as well a local haemostasis, should be
provided. Approximately 20% of argatroban can be cleared
through dialysis.
Miscellaneous
Drug interactions: No drug interactions have been identi-
fied so far.
Bivalirudin (Angiox®)
Regulatory status
EU
– Prophylaxis in patients with acute coronary syndrome
(ACS) undergoing percutaneous coronary intervention
(PCI) [44, 45].
FDA
– Prophylaxis in patients with, or at risk of HIT, or with
HIT and thrombosis undergoing PCI [16].
Pharmacokinetics/pharmacodynamics
Molecule: Bivalirudin is a small (molecular weight 2180
Daltons), direct, selective, reversible and bivalent throm-
bin inhibitor. The bivalent binding properties contribute to
bivalirudin’s high affinity and high specificity for throm-
bin. Bivalirudin does not require antithrombin for its anti-
coagulant activity (hence “direct”).
Distribution: Plasma and extracellular fluid; no protein
binding apart from thrombin.
Metabolism: Proteolytic inactivation (80%); renal excre-
tion (20%).
Excretion: Hepatobiliary and renal clearance.
Half-life: 25 minutes.
How to use the drug in patients with HIT
The WPH recommends the use of bivalirudin in acute HIT
patients in the setting of urgent coronary angioplasty –
PCI (see references [44, 45] for dosing) and as an option
in HIT patients requiring cardiac surgery. Bivalirudin has
been evaluated in HIT patients outside the context of car-
diac surgery and PCI [25–27]. The WPH suggests the use
of bivalirudin in HIT patients in an intensive care setting.
Bivalirudin is administered as a continuous intravenous in-
Figure 1: Proposed algorithm for transitioning patients from argatroban to vitamin K antagonists (VKA) [15, 41, 42].
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fusion without a bolus. Table 3 summarises the WPH rec-
ommended dosing schedules of bivalirudin in HIT patients
[2, 25–27].
How to use the drug in HIT subpopulations
Renal insufficiency: No dosage adjustment is necessary in
patients with mild renal insufficiency. In the case of mod-
erate or severe renal insufficiency or in the presence of
chronic renal replacement therapy, dosing should be adapt-
ed. Patients should be monitored by assessing aPTT and/
or bivalirudin plasma concentration measured as anti-fac-
tor IIa activity (see “Monitoring”).
Liver insufficiency: No dosage adjustment is necessary in
patients with hepatic dysfunction.
Pregnancy: Insufficient evidence. It is not known whether
the drug is excreted into breast milk [34–36].
Geriatrics: The effectivity of bivalirudin does not seem to
be affected by age. However, there are insufficient data
to determine if its absorption, distribution, and elimination
are different in elderly patients (≥65 years).
Paediatrics: Insufficient evidence.
Monitoring
Bivalirudin prolongs thrombin-based coagulation tests
(PT, aPTT, TT, ACT) in a concentration-dependent man-
ner. Daily bivalirudin concentration assessment by anti-
factor IIa testing is the preferred monitoring modality, fol-
lowed by aPTT monitoring. Anti-factor IIa and/or aPTT
monitoring should be started before and repeated 3 hours
after the start of the bivalirudin infusion (steady-state lev-
els of drug and anticoagulant effect are typically attained
after five half-lives), 3 hours after each dose adjustment
and then daily.
Target ranges for the various tests have not been estab-
lished in an outcome-based setting. In the experience of the
authors, a target concentration of 1.0 µg/ml with a range of
0.5–1.5 µg/ml for the anti-factor IIa test is a practicable tar-
get range [25]. The 1.5 to 2.5 fold increase of basal aPTT is
defined as a target in the prescribing information (provid-
ed aPTT is within the reference range at baseline); howev-
er, every laboratory should establish in-house target ranges
with its own reagent/coagulometer combination [25]. In
the eyes of the WPH members, aPTT and ACT should
also be locally calibrated based on a validated anti-factor
IIa whenever possible [25]. A single centre retrospective
study comparing argatroban with bivalirudin showed that
HIT patients receiving bivalirudin reached the aPTT-based
target range more rapidly than patients treated with arga-
troban [46]. Whether or not this results in a clinical benefit
has not been determined.
Conversion to oral anticoagulant therapy with vitamin
K antagonists
PT and INR are dose dependently influenced by bi-
valirudin. This aspect needs to be considered during the
transition to a VKA (see also paragraph in the Introduction
regarding conditions necessary prior to transitioning to a
VKA). In our experience, a therapeutic bivalirudin con-
centration increases the INR by about 1.0 [25]. Therefore,
we suggest aiming for an INR of 3–4 for two consecutive
days when bivalirudin and VKA are co-administered and
to check the INR 3–6 hours after stopping bivalirudin.
Safety
Specific contraindications
– Severe renal insufficiency.
Caution
Caution is recommended in patients with increased risk of
bleeding, such as patients with uncontrolled hypertension,
inherited or acquired bleeding disorders, gastrointestinal
lesions, or immediately following lumbar puncture, spinal
anaesthesia or major surgery. Caution is also recommended
in patients with any other form of anticoagulation or with
antiplatelet therapy. Bivalirudin can easily diffuse into the
extravascular space (third compartment) when this is in-
creased owing to overhydration.
In patients with an elevated baseline aPTT, it is especially
important to monitor bivalirudin using drug levels (a vali-
dated anti-factor IIa assay) rather than using the aPTT [43].
Antidote
No specific antidote for bivalirudin is available. However,
bivalirudin’s short half-life reduces the need for an anti-
dote.
Management of bleeding
No specific recommendations has been defined. Anticoag-
ulation parameters typically return to baseline within two
to four half-lives after discontinuation of the drug. Symp-
tomatic and supportive therapy should be provided. Bi-
valirudin can be cleared through dialysis, haemofiltration
and plasmapheresis [44, 45].
Miscellaneous
Drug interactions: No drug interactions have been report-
ed so far.
Concomitant medications: The following medications
should not be infused over the same intravenous line: al-
teplase, amiodarone, amphotericin B, diazepam, dobuta-
mine, haloperidol, labetalol, vancomycin (see references
[44, 45] for a complete list).
Overdose: Because of low protein binding, overdosing can
be treated by use of haemodialysis, haemofiltration and
plasmapheresis. Elimination may vary according to the
type of filter membrane [47, 48].
Danaparoid sodium (Orgaran®)
Regulatory status
Swissmedic
– Prophylaxis or treatment of venous thromboembolism
(VTE) in patients with, or at risk of, HIT requiring par-
enteral anticoagulation.
– Prophylaxis and treatment of deep vein thrombosis
(DVT), in particular following major surgery [15].
FDA
– Prophylaxis of postoperative DVT, which may lead to
pulmonary embolism, in patients undergoing elective
hip replacement surgery [16].
Review article: Medical guidelines Swiss Med Wkly. 2020;150:w20210
Swiss Medical Weekly · PDF of the online version · www.smw.ch
Published under the copyright license “Attribution – Non-Commercial – No Derivatives 4.0”.
No commercial reuse without permission. See http://emh.ch/en/services/permissions.html.
Page 8 of 14
Pharmacokinetics/pharmacodynamics
Molecule: Danaparoid sodium is a small heparinoid con-
sisting of glycosaminoglycans, with a mean molecular
weight of 5500 Daltons. Danaparoid catalyses the an-
tithrombin-mediated inactivation of factor Xa, leading to
inhibition of thrombin generation. Factor IIa (thrombin) is
inactivated to a much lesser extent (anti-factor Xa : anti-
factor IIa ratio = 20:1) than in the presence of unfraction-
ated heparin or low molecular weight heparins.
Distribution: The distribution volume of anti-factor Xa ac-
tivity has been estimated to be 8–9 L.
Metabolism: No evidence of hepatic metabolism.
Excretion: Predominantly renal clearance.
Half-life: 19–25 hours.
How to use the drug in patients with HIT
The WPH recommends the use of danaparoid in HIT pa-
tients as an intravenous infusion, with an initial weight-
adapted bolus followed by an accelerated initial infusion
and maintenance infusion, for example, as indicated in the
Swiss compendium [15]. If intravenous infusion is not de-
sirable, danaparoid may be administered subcutaneously.
Table 3 summarises dosing schedules of danaparoid [19,
20, 49].
How to use the drug in HIT subpopulations
Renal Insufficiency: Because of its predominantly renal ex-
cretion, elimination of danaparoid (measured as anti-fac-
tor Xa activity) is prolonged in renal insufficiency. Care-
ful monitoring of anti-factor Xa activity is recommended
in this case.
Liver insufficiency: No evidence available.
Pregnancy: Limited evidence supports the use of dana-
paroid during pregnancy and breast-feeding (no or no sig-
nificant anti-factor Xa activity in cord blood or breast
milk), but a benefit-risk assessment is recommended
[34–36].
Geriatrics: The effectivity of danaparoid does not seem
to be affected by age. However, there are insufficient data
to determine if its absorption, distribution, and elimination
are different in elderly patients (≥65 years).
Paediatrics: Limited evidence is available. Dose recom-
mendations are found in the Swiss compendium [15].
Monitoring
As a result of its predominant anti-factor Xa activity, dana-
paroid has little or no effect on routine coagulation assays
such as PT, aPTT or TT. The preferred monitoring modal-
ity is an anti-factor Xa activity assay, calibrated for dana-
paroid. The therapeutic plasma anti-factor Xa range is
0.5–0.7 U/ml 5 to 10 minutes after bolus, up to 1.0 U/ml
during the adjustment phase in the first hours of adminis-
tration, and 0.5–0.8 U/ml during maintenance infusion [19,
20, 49].
Conversion to oral anticoagulant therapy with vitamin
K antagonists
Transition to a VKA is considered straightforward, as PT
and INR are not affected by danaparoid. Therefore, we
suggest aiming for an INR within the therapeutic range on
two consecutive days when danaparoid and VKA are co-
administered before stopping danaparoid.
Safety
Specific contraindications
– Patients with severe renal and hepatic insufficiency, un-
less no other antithrombotic treatment is available for
HIT [15].
Caution
Caution is recommended in patients displaying cross-reac-
tivity between danaparoid and HIT-Abs. Cross-reactivity
is observed in approximately 5% of patients, in whom
discontinuation of danaparoid is recommended to prevent
treatment failure. Routine testing is not recommended but
platelet counts should be monitored initially. Caution is al-
so recommended in patients with hypersensitivity to sul-
phites.
Antidote
No specific antidote for danaparoid is available. Andex-
anet alfa (a potential direct antagonist) is not yet available
in Switzerland.
Management of bleeding
Discontinuation of danaparoid followed by symptomatic
and supportive treatment should be provided to the bleed-
ing patient. Plasma exchange can be considered if con-
ventional treatment is not sufficient. Protamine sulphate
partially neutralises anti-factor Xa activity and can be co-
administered safely; however, there is no evidence that it is
effective in controlling severe bleeding during danaparoid
treatment.
Miscellaneous
Drug interactions: Limited evidence that oral chlorthali-
done increases the distribution volume of anti-factor IIa ac-
tivity, and decreases the clearance and distribution volume
of anti-factor Xa activity [15].
Fondaparinux (Arixtra®)
Regulatory status
Swissmedic
– Prevention of VTE, which may lead to pulmonary em-
bolism, in patients undergoing major orthopaedic
surgery.
– Prevention of VTE in patients at risk of VTE who are
immobilised owing to an acute disease such as cardiac
insufficiency, acute respiratory insufficiency, or an
acute infection or inflammation.
– Prevention of VTE in patients undergoing abdominal
surgery who are at risk for thromboembolic complica-
tions.
– Treatment of acute DVT and pulmonary embolism
when administered in conjunction with anticoagulation
therapy with VKA.
– Treatment of ACS (unstable angina pectoris or non-ST-
elevation myocardial infarction).
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– Treatment of acute ST-elevation myocardial infarction
combined with lysis therapy, or when lysis therapy or
primary PCI are excluded [15].
FDA
– Prevention of VTE, which may lead to pulmonary em-
bolism, in patients undergoing major orthopaedic
surgery.
– Prevention of VTE in patients undergoing abdominal
surgery who are at risk for thromboembolic complica-
tions.
– Treatment of acute DVT without pulmonary embolism
when administered in conjunction with warfarin sodium
and for the treatment of acute pulmonary embolism
when administered in conjunction with warfarin sodium
[16].
Although the use of fondaparinux is off-label both in acute
HIT complicated by thrombosis and in acute HIT without
thrombosis, there are several publications reporting its use-
fulness, even as initial anticoagulant in acute HIT [50, 51].
Pharmacokinetics/pharmacodynamics
Molecule: Fondaparinux is a pentasaccharide (molecular
weight 11,728 Daltons). It strongly binds to antithrombin
and thereby enhances inactivation of factor Xa without in-
teraction with factor IIa or platelets. Compared with he-
parins, fondaparinux has a lower affinity to PF4 and does
not induce its immunogenic conformational changes [52].
Distribution: Blood; no significant plasma protein binding.
Metabolism: No evidence of hepatic metabolism.
Excretion: Renal clearance.
Half-life: 17–21 hours.
How to use the drug in patients with HIT
The WPH recommends the use of fondaparinux in selected
HIT patients as a subcutaneous injection without bolus.
Since there is no immunogenic conformational change of
PF4, no cross-reactivity is expected, but a few cases of fon-
daparinux-associated thrombocytopenia resembling HIT
have been reported [53]. Table 3 summarises dosing sched-
ules of fondaparinux [21, 28, 54–56].
How to use the drug in HIT subpopulations
Renal insufficiency: In the presence of impaired renal func-
tion, caution is warranted because of possible drug accu-
mulation. Consider dose reduction according to the Swiss
compendium [15]. Contraindicated when creatinine clear-
ance is <30 ml/min, and caution is necessary during pro-
longed treatment when creatinine clearance is between 30
and 50 ml/min.
Liver insufficiency: Use with caution in severe liver insuf-
ficiency owing to elevated haemorrhagic risk.
Pregnancy: Limited information on the use of fondaparin-
ux in pregnant and breast-feeding women is available.
Therefore, it should be administered with caution during
pregnancy and breast-feeding [34–36].
Geriatrics: The effectivity of fondaparinux does not seem
to be affected by age.
Paediatrics: Limited supportive evidence on the use of
fondaparinux in children is available. A possible approach
is to start treatment of DVT with a daily dosage between
0.1 and 0.15 mg per kg body weight subcutaneously and
adjust dosage if peak drug concentration is below 0.6 or
above 1.5 μg/ml.
Monitoring
Fondaparinux used in licensed indications does not require
monitoring. If used in subpopulations or special situations,
knowledge of the plasma concentration can be helpful for
safety reasons. Chromogenic assay of anti-factor Xa activ-
ity calibrated with fondaparinux produces reliable results.
Recommended time for measurement of plasma concen-
trations is 3–5 hours after application (target peak plasma
concentration: 1.0–1.5 µg/ml) or before next application
(target trough level: 0.4–0.6 µg/ml) [57–59]. Fondaparinux
has no impact on routine coagulation tests.
Conversion to oral anticoagulant therapy with vitamin
K antagonists
PT and INR are not influenced by fondaparinux. There-
fore, we suggest aiming for an INR within the therapeutic
range for two consecutive days when fondaparinux and
VKA are co-administered before stopping fondaparinux.
Safety
Specific contraindications
– Severe renal impairment.
Antidote
No specific antidote for fondaparinux is available. An-
dexanet alfa (a direct antagonist) is not yet available in
Switzerland.
Management of major bleeding
Recombinant factor VIIa is able to normalise prolonged PT
and aPTT, as well as changes in thrombin generation seen
during treatment with fondaparinux [60, 61]. In HIT pa-
tients caution is advocated with the use of all haemostatic
agents because of the increased thrombotic risk. Moreover,
prothrombin complex concentrate (PCC) usually contain
low amounts of heparin that may re-activate HIT.
Miscellaneous
Drug interactions: No drug interactions have been report-
ed in the literature.
Direct oral anticoagulants: efficacy and safety
of DOACs in HIT patients
DOACs are increasingly used worldwide. However, the
clinical data supporting their application in patients with
HIT is even more limited than the data collected with
the other anticoagulants mentioned above. No randomised
controlled trials are available and even large cohort studies
are lacking. Nevertheless, because of their ease of use and
favourable characteristics, DOACs have been used for an-
ticoagulant treatment of acute HIT, though only a few case
series and small cohort studies are available.
In a prospective cohort study, Linkins and co-workers en-
rolled 22 patients with suspected HIT (including 12 pa-
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tients with definite HIT) and treated them with rivaroxaban
15 mg twice daily (followed by 20 mg; after an initial
course of fondaparinux in six patients) [62]. Platelet re-
covery was observed in all patients but one. One recurrent
thromboembolic event occurred, and one patient required
limb amputation. Sharifi and co-workers reported on 22
retrospectively identified patients with suspected HIT, who
were treated with dabigatran (150 mg twice daily), rivarox-
aban (20 mg once daily) or apixaban (5 mg twice daily)
following an initial course of argatroban [63]. No throm-
boembolic or bleeding events occurred, but six patients
died for various reasons. Warkentin et al. reported in a
small series of patients the experience in Hamilton (Cana-
da) and performed a review of the literature concluding
that DOACs, in particular rivaroxaban, seem to be safe and
effective for the treatment of acute HIT [13]. Davis and co-
workers retrospectively observed 12 patients with suspect-
ed HIT (definite HIT in four cases), who were treated with
apixaban (2.5–10 mg twice daily) or rivaroxaban (15 mg
twice daily) [64]. Besides these studies, 54 case reports are
available (reviewed in [65]).
Even though these reports are encouraging, the WPH
members emphasise the need for caution regarding the use
of DOACs as the initial anticoagulant in HIT patients, as
supporting clinical evidence is currently limited. DOACs
may be considered when switching to oral anticoagulation
if there are neither renal insufficiency nor liver impair-
ment. Of the DOACs, we would give preference to ri-
varoxaban, given that the most experience is available for
this DOAC [12, 66]. Moreover, because current literature
for the use of DOACs in this setting remains limited,
DOACs should not be the first option when an arterial
thrombotic event occurred during HIT [12, 66].
Finally, DOACs should not be used during pregnancy and
breast feeding [15, 34–36].
Rivaroxaban (Xarelto®)
Regulatory status
Currently there are only limited data regarding the use of
rivaroxaban in HIT, and data on efficacy and safety of this
drug in HIT are still limited.
Swissmedic
– Prophylaxis of VTE after major orthopaedic surgery of
the lower limbs such as hip and knee replacement
surgery.
– Treatment of VTE and prophylaxis of a recurrent DVT
and pulmonary embolism.
– Stroke prevention and prophylaxis of systemic em-
bolism in non-valvular atrial fibrillation [15].
FDA
– Prevention of stroke and systemic embolism in patients
with non-valvular atrial fibrillation.
– Prophylaxis of DVT, which may lead to pulmonary em-
bolism, in patients undergoing knee or hip replacement
surgery.
– Secondary prevention of venous thromboembolism af-
ter completing at least 6 months of anticoagulation ther-
apy [16].
Pharmacokinetics/pharmacodynamics
Molecule: Rivaroxaban is a small synthetic molecule with
a molecular weight of 436 Daltons, which strongly binds
to and inhibits factor Xa.
Distribution: Plasma; plasma protein binding (albumin) of
92–95%.
Metabolism: Two thirds of the dose is metabolised in the
liver. Half of the metabolised drug is excreted via the kid-
neys as inactive components, and the other half via the he-
patobiliary route.
Excretion: One third of the dose is directly excreted via the
kidneys as unchanged active compound.
Half-life: 5–9 hours, in elderly patients 11–13 hours.
Table 1 summarises the pharmacokinetic properties of ri-
varoxaban and other anticoagulants.
Antidote
No specific antidote for rivaroxaban is currently available
in Switzerland. Andexanet alfa is an antidote to factor Xa
antagonists approved by the FDA under the name An-
dexxa [67] and has been conditionally authorised by the
European Medicines Agency (EMA) under the name On-
dexxya [68]. The approval of Swissmedic is still pending.
In order to avoid absorption of rivaroxaban in the event of
an overdose, the use of activated charcoal may be consid-
ered where tablets have been taken within the previous 8
hours [69]. Absorption of rivaroxaban is subject to satura-
tion: the rivaroxaban concentration in plasma only increas-
es negligibly at oral doses >50 mg (ceiling effect) [70].
Management of major bleeding
In animal models, recombinant factor VIIa as well as PCC
were able to stop bleeding in patients treated with DOACs.
Moreover, PCC was able to normalise prolonged PT and
aPTT ex vivo, induced by ingestion of rivaroxaban by
healthy subjects. In addition, a number of case reports
exist, with successful treatment of rivaroxaban-associated
bleedings with PCC at a dose of 25 U/kg [71, 72].
Miscellaneous
Drug interactions: rivaroxaban is metabolised via cy-
tochrome P450 (CYP) 3A4, CYP2J2 and CYP-indepen-
dent biotransformation processes. Furthermore, in vitro
studies indicate the drug to be a substrate of P-glycopro-
tein. For the respective possible interactions, see the Swiss
compendium [15].
Conclusions
Our recommendations integrate multiple guidelines re-
garding the anticoagulation of patients with HIT [1, 12, 25,
34, 73]. They propose that argatroban, bivalirudin, dana-
paroid, fondaparinux and DOACs are potentially suitable
anticoagulants for the treatment of patients with HIT in
Switzerland and provide guidance on selecting anticoagu-
lants for individual patients with HIT and special condi-
tions. Our recommendations also provide information re-
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garding adequate drug dosage and monitoring in special
clinical situations.
The limitations of our recommendations are inherent to the
(very) low level of the evidence that we identified for most
aspects related to the anticoagulants used to treat patients
with HIT.
In conclusion, we hope that our recommendations will sup-
port Swiss clinicians treating HIT patients with anticoagu-
lants in different clinical conditions.
Disclosure statement
AC has received grants from CSL Behring and NovoNordisk and non-
financial support from Bayer and Shire. LA received grants/research
support from: Bayer, CSL-Behring, Novartis, NovoNordisk, Roche,
Shire-Takeda, and Sobi; support for the CHUV hemophilia nurses
programme from: CSL-Behring, Bayer, NovoNordisk, Octapharma,
Roche, Shire, and Sobi; honoraria for participating in scientific ad-
visory boards: Bayer, Boehringer Ingelheim, Daiichi Sankyo,
NovoNordisk, OrPha Swiss, Pfizer, Roche, Shire/Baxalta, Sobi; hon-
oraria as consultant/speaker: Bayer, Sanofi-Genzyme, Siemens. J-DS
received lecture and advisory honoraria from: Alexion, Bayer, BMS-
Pfizer, Sanofi, Shire-Takeda, Siemens Diagnostics. All other authors
report no relevant conflict of interest.
References
1 Linkins LA, Dans AL, Moores LK, Bona R, Davidson BL, Schulman S,
et al. Treatment and prevention of heparin-induced thrombocytopenia:
Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: Ameri-
can College of Chest Physicians Evidence-Based Clinical Practice
Guidelines. Chest. 2012;141(2, Suppl):e495S–530S. doi:
http://dx.doi.org/10.1378/chest.11-2303. PubMed.
2 Warkentin TE, Anderson JA. How I treat patients with a history of he-
parin-induced thrombocytopenia. Blood. 2016;128(3):348–59. doi:
http://dx.doi.org/10.1182/blood-2016-01-635003. PubMed.
3 Nagler M, Bachmann LM, ten Cate H, ten Cate-Hoek A. Diagnostic val-
ue of immunoassays for heparin-induced thrombocytopenia: a systemat-
ic review and meta-analysis. Blood. 2016;127(5):546–57. doi:
http://dx.doi.org/10.1182/blood-2015-07-661215. PubMed.
4 Leroux D, Hezard N, Lebreton A, Bauters A, Suchon P, de Maistre E, et
al. Prospective evaluation of a rapid nanoparticle-based lateral flow im-
munoassay (STic Expert(®) HIT) for the diagnosis of heparin-induced
thrombocytopenia. Br J Haematol. 2014;166(5):774–82. doi:
http://dx.doi.org/10.1111/bjh.12939. PubMed.
5 Linkins LA, Bates SM, Lee AY, Heddle NM, Wang G, Warkentin TE.
Combination of 4Ts score and PF4/H-PaGIA for diagnosis and manage-
ment of heparin-induced thrombocytopenia: prospective cohort study.
Blood. 2015;126(5):597–603. doi: http://dx.doi.org/10.1182/
blood-2014-12-618165. PubMed.
6 Nellen V, Sulzer I, Barizzi G, Lämmle B, Alberio L. Rapid exclusion or
confirmation of heparin-induced thrombocytopenia: a single-center ex-
perience with 1,291 patients. Haematologica. 2012;97(1):89–97. doi:
http://dx.doi.org/10.3324/haematol.2011.048074. PubMed.
7 Arepally GM. Heparin-induced thrombocytopenia. Blood.
2017;129(21):2864–72. doi: http://dx.doi.org/10.1182/
blood-2016-11-709873. PubMed.
8 Warkentin TE. High-dose intravenous immunoglobulin for the treatment
and prevention of heparin-induced thrombocytopenia: a review. Expert
Rev Hematol. 2019;12(8):685–98. doi: http://dx.doi.org/10.1080/
17474086.2019.1636645. PubMed.
9 Warkentin TE, Climans TH, Morin PA. Intravenous Immune Globulin to
Prevent Heparin-Induced Thrombocytopenia. N Engl J Med.
2018;378(19):1845–8. doi: http://dx.doi.org/10.1056/NEJMc1801799.
PubMed.
10 Pon TK, Mahajan A, Rosenberg A, Amin A, Shah D, Jenkins I, et al.
Platelet response to direct thrombin inhibitor or fondaparinux treatment
in patients with suspected heparin-induced thrombocytopenia. J Thromb
Thrombolysis. 2018;45(4):536–42. doi: http://dx.doi.org/10.1007/
s11239-018-1646-x. PubMed.
11 Warkentin TE, Kelton JG. Temporal aspects of heparin-induced throm-
bocytopenia. N Engl J Med. 2001;344(17):1286–92. doi:
http://dx.doi.org/10.1056/NEJM200104263441704. PubMed.
12 Cuker A, Arepally GM, Chong BH, Cines DB, Greinacher A, Gruel Y,
et al. American Society of Hematology 2018 guidelines for management
of venous thromboembolism: heparin-induced thrombocytopenia. Blood
Adv. 2018;2(22):3360–92. doi: http://dx.doi.org/10.1182/bloodad-
vances.2018024489. PubMed.
13 Warkentin TE, Pai M, Linkins LA. Direct oral anticoagulants for treat-
ment of HIT: update of Hamilton experience and literature review.
Blood. 2017;130(9):1104–13. doi: http://dx.doi.org/10.1182/
blood-2017-04-778993. PubMed.
14 Greinacher A. Heparin-Induced Thrombocytopenia. N Engl J Med.
2015;373(3):252–61. doi: http://dx.doi.org/10.1056/NEJMcp1411910.
PubMed.
15 www.compendium.ch.
16 https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm.
17 Borbe H, Müller J. Argatra Produktmonographie. Deutschland GmH:
Mitsubishi Pharma; 2013.
18 Tatsuno J, Komatsu T, Iida S. Pharmacokinetic studies of argatroban
(MD-805): Protein binding and blood cell binding. Jap Pharmacol Ther.
1986;14(suppl 5):243–9.
19 de Valk HW, Banga JD, Wester JW, Brouwer CB, van Hessen MW,
Meuwissen OJ, et al. Comparing subcutaneous danaparoid with intra-
venous unfractionated heparin for the treatment of venous thromboem-
bolism. A randomized controlled trial. Ann Intern Med.
1995;123(1):1–9. doi: http://dx.doi.org/10.7326/
0003-4819-123-1-199507010-00001. PubMed.
20 Ibbotson T, Perry CM. Danaparoid: a review of its use in thromboem-
bolic and coagulation disorders. Drugs. 2002;62(15):2283–314. doi:
http://dx.doi.org/10.2165/00003495-200262150-00016. PubMed.
21 Nagler M, Haslauer M, Wuillemin WA. Fondaparinux - data on efficacy
and safety in special situations. Thromb Res. 2012;129(4):407–17. doi:
http://dx.doi.org/10.1016/j.thromres.2011.10.037. PubMed.
22 Shepherd MF, Jacobsen JM, Rosborough TK. Argatroban therapy using
enzymatic anti-factor IIa monitoring. Ann Pharmacother.
2011;45(3):422–3. doi: http://dx.doi.org/10.1345/aph.1P274. PubMed.
23 Lewis BE, Wallis DE, Berkowitz SD, Matthai WH, Fareed J, Walenga
JM, et al.; ARG-911 Study Investigators. Argatroban anticoagulant ther-
apy in patients with heparin-induced thrombocytopenia. Circulation.
2001;103(14):1838–43. doi: http://dx.doi.org/10.1161/
01.CIR.103.14.1838. PubMed.
24 Lewis BE, Wallis DE, Leya F, Hursting MJ, Kelton JG; Argatroban-915
Investigators. Argatroban anticoagulation in patients with heparin-in-
duced thrombocytopenia. Arch Intern Med. 2003;163(15):1849–56. doi:
http://dx.doi.org/10.1001/archinte.163.15.1849. PubMed.
25 Colucci G, Nagler M, Klaus N, Conte T, Giabbani E, Alberio L. Practi-
cal guidelines for Argatroban and Bivalirudin in patients with Heparin-
induced Thrombocytopenia. J Transl Sci. 2015;1(2):37–42. doi:
http://dx.doi.org/10.15761/JTS.1000109.
26 Kiser TH, Fish DN. Evaluation of bivalirudin treatment for heparin-in-
duced thrombocytopenia in critically ill patients with hepatic and/or re-
nal dysfunction. Pharmacotherapy. 2006;26(4):452–60. doi:
http://dx.doi.org/10.1592/phco.26.4.452. PubMed.
27 Sciulli TM, Mauro VF. Pharmacology and clinical use of bivalirudin.
Ann Pharmacother. 2002;36(6):1028–41. doi: http://dx.doi.org/10.1345/
aph.1A197. PubMed.
28 Pistulli R, Oberle V, Figulla HR, Yilmaz A, Pfeifer R. Fondaparinux
cross-reacts with heparin antibodies in vitro in a patient with fondaparin-
ux-related thrombocytopenia. Blood Coagul Fibrinolysis.
2011;22(1):76–8. doi: http://dx.doi.org/10.1097/
MBC.0b013e328340ff24. PubMed.
29 Bartholomew JR, Pietrangeli CE, Hursting MJ. Argatroban anticoagula-
tion for heparin-induced thrombocytopenia in elderly patients. Drugs
Aging. 2007;24(6):489–99. doi: http://dx.doi.org/10.2165/
00002512-200724060-00005. PubMed.
30 Skrupky LP, Smith JR, Deal EN, Arnold H, Hollands JM, Martinez EJ,
et al. Comparison of bivalirudin and argatroban for the management of
heparin-induced thrombocytopenia. Pharmacotherapy.
2010;30(12):1229–38. doi: http://dx.doi.org/10.1592/phco.30.12.1229.
PubMed.
31 Levine RL, Hursting MJ, McCollum D. Argatroban therapy in heparin-
induced thrombocytopenia with hepatic dysfunction. Chest.
2006;129(5):1167–75. doi: http://dx.doi.org/10.1378/chest.129.5.1167.
PubMed.
32 Murray PT, Reddy BV, Grossman EJ, Hammes MS, Trevino S, Ferrell
J, et al. A prospective comparison of three argatroban treatment regi-
mens during hemodialysis in end-stage renal disease. Kidney Int.
2004;66(6):2446–53. doi: http://dx.doi.org/10.1111/
j.1523-1755.2004.66022.x. PubMed.
33 Swan SK, Hursting MJ. The pharmacokinetics and pharmacodynamics
of argatroban: effects of age, gender, and hepatic or renal dysfunction.
Pharmacotherapy. 2000;20(3):318–29. doi: http://dx.doi.org/10.1592/ph-
co.20.4.318.34881. PubMed.
Review article: Medical guidelines Swiss Med Wkly. 2020;150:w20210
Swiss Medical Weekly · PDF of the online version · www.smw.ch
Published under the copyright license “Attribution – Non-Commercial – No Derivatives 4.0”.
No commercial reuse without permission. See http://emh.ch/en/services/permissions.html.
Page 12 of 14
34 Bates SM, Greer IA, Pabinger I, Sofaer S, Hirsh J. Venous thromboem-
bolism, thrombophilia, antithrombotic therapy, and pregnancy: Ameri-
can College of Chest Physicians Evidence-Based Clinical Practice
Guidelines (8th Edition). Chest. 2008;133(6, Suppl):844S–86S. doi:
http://dx.doi.org/10.1378/chest.08-0761. PubMed.
35 Fogerty AE. Challenges of Anticoagulation Therapy in Pregnancy. Curr
Treat Options Cardiovasc Med. 2017;19(10):76. doi: http://dx.doi.org/
10.1007/s11936-017-0575-x. PubMed.
36 Lindhoff-Last E, Bauersachs R. Heparin-induced thrombocytopenia-al-
ternative anticoagulation in pregnancy and lactation. Semin Thromb He-
most. 2002;28(5):439–46. doi: http://dx.doi.org/10.1055/s-2002-35284.
PubMed.
37 Lewis B, Hursting M. Argatroban therapy in heparin-induced thrombo-
cytopenia. In: Warkentin T, Greinacher A, editors. Heparin-induced
thrombocytopenia. New York, Basel: Marcel Dekker; 2006.
38 Tardy-Poncet B, Nguyen P, Thiranos JC, Morange PE, Biron-Andréani
C, Gruel Y, et al. Argatroban in the management of heparin-induced
thrombocytopenia: a multicenter clinical trial. Crit Care.
2015;19(1):396. doi: http://dx.doi.org/10.1186/s13054-015-1109-0.
PubMed.
39 Siegmund R, Boer K, Poeschel K, Wolf G, Deufel T, Kiehntopf M. In-
fluence of direct thrombin inhibitor argatroban on coagulation assays in
healthy individuals, patients under oral anticoagulation therapy and pa-
tients with liver dysfunction. Blood Coagul Fibrinolysis.
2008;19(4):288–93. doi: http://dx.doi.org/10.1097/
MBC.0b013e3282fe73ec. PubMed.
40 Zhang L, Yang J, Zheng X, Fan Q, Zhang Z. Influences of argatroban on
five fibrinogen assays. Int J Lab Hematol. 2017;39(6):641–4. doi:
http://dx.doi.org/10.1111/ijlh.12719. PubMed.
41 Cuker A, Cines DB. How I treat heparin-induced thrombocytopenia.
Blood. 2012;119(10):2209–18. doi: http://dx.doi.org/10.1182/
blood-2011-11-376293. PubMed.
42 Sheth SB, DiCicco RA, Hursting MJ, Montague T, Jorkasky DK. Inter-
preting the International Normalized Ratio (INR) in individuals receiv-
ing argatroban and warfarin. Thromb Haemost. 2001;85(3):435–40. doi:
http://dx.doi.org/10.1055/s-0037-1615601. PubMed.
43 Warkentin TE. Anticoagulant failure in coagulopathic patients: PTT
confounding and other pitfalls. Expert Opin Drug Saf.
2014;13(1):25–43. doi: http://dx.doi.org/10.1517/
14740338.2013.823946. PubMed.
44 https://ec.europa.eu/health/documents/community-register/2017/
20170914138919/anx_138919_de.pdf.
45 https://www.accord-healthcare.de/sites/default/files/2018-06/FI_Bi-
valirudin_Stand%20102016.pdf.
46 Vo QA, Lin JK, Tong LM. Efficacy and safety of argatroban and bi-
valirudine in patients with suspected heparin-induced thrombocytopenia.
Ann Pharmacother. 2015;49(2):178–84. doi: http://dx.doi.org/10.1177/
1060028014562949. PubMed.
47 Bartholomew JR. Bivalirudin for the treatment of heparin-induced
thrombocytopenia. In: Warkentin TE, Greinacher A, editors. Heparin-in-
duced thrombocytopenia. 4th edition. London, UK: Informa Healthcare;
2007. p. 409–39.
48 Koster A, Chew D, Gründel M, Bauer M, Kuppe H, Spiess BD. Bi-
valirudin monitored with the ecarin clotting time for anticoagulation
during cardiopulmonary bypass. Anesth Analg. 2003;96(2):383–6. doi:
http://dx.doi.org/10.1213/00000539-200302000-00015. PubMed.
49 Stiekema JC, Wijnand HP, Van Dinther TG, Moelker HC, Dawes J,
Vinchenzo A, et al. Safety and pharmacokinetics of the low molecular
weight heparinoid Org 10172 administered to healthy elderly volunteers.
Br J Clin Pharmacol. 1989;27(1):39–48. doi: http://dx.doi.org/10.1111/
j.1365-2125.1989.tb05333.x. PubMed.
50 Schindewolf M, Steindl J, Beyer-Westendorf J, Schellong S, Dohmen
PM, Brachmann J, et al. Use of Fondaparinux Off-Label or Approved
Anticoagulants for Management of Heparin-Induced Thrombocytopenia.
J Am Coll Cardiol. 2017;70(21):2636–48. doi: http://dx.doi.org/10.1016/
j.jacc.2017.09.1099. PubMed.
51 Linkins LA, Hu G, Warkentin TE. Systematic review of fondaparinux
for heparin-induced thrombocytopenia: When there are no randomized
controlled trials. Res Pract Thromb Haemost. 2018;2(4):678–83. doi:
http://dx.doi.org/10.1002/rth2.12145. PubMed.
52 Kreimann M, Brandt S, Krauel K, Block S, Helm CA, Weitschies W, et
al. Binding of anti-platelet factor 4/heparin antibodies depends on the
thermodynamics of conformational changes in platelet factor 4. Blood.
2014;124(15):2442–9. doi: http://dx.doi.org/10.1182/
blood-2014-03-559518. PubMed.
53 Warkentin TE. Fondaparinux: does it cause HIT? Can it treat HIT? Ex-
pert Rev Hematol. 2010;3(5):567–81. doi: http://dx.doi.org/10.1586/
ehm.10.54. PubMed.
54 D’Angelo A, Valle PD, Fattorini A, Luciano C. Disappearance of anti-
PF4/heparin antibodies under prolonged fondaparinux administration in
a patient with DVT associated with LMWH-induced thrombocytopenia.
Thromb Haemost. 2006;95(3):573–5. doi: http://dx.doi.org/10.1160/
TH05-11-0722. PubMed.
55 Lobo B, Finch C, Howard A, Minhas S. Fondaparinux for the treatment
of patients with acute heparin-induced thrombocytopenia. Thromb
Haemost. 2008;99(1):208–14. doi: http://dx.doi.org/10.1160/
TH07-04-0252. PubMed.
56 Warkentin TE, Cook RJ, Marder VJ, Sheppard JA, Moore JC, Eriksson
BI, et al. Anti-platelet factor 4/heparin antibodies in orthopedic surgery
patients receiving antithrombotic prophylaxis with fondaparinux or
enoxaparin. Blood. 2005;106(12):3791–6. doi: http://dx.doi.org/10.1182/
blood-2005-05-1938. PubMed.
57 www.pathology.med.umich.edu.
58 Depasse F, Gerotziafas GT, Busson J, Van Dreden P, Samama MM. As-
sessment of three chromogenic and one clotting assays for the measure-
ment of synthetic pentasaccharide fondaparinux (Arixtra) anti-Xa activi-
ty. J Thromb Haemost. 2004;2(2):346–8. doi: http://dx.doi.org/10.1111/
j.1538-7933.2004.0584a.x. PubMed.
59 Garcia DA, Baglin TP, Weitz JI, Samama MM. Parenteral anticoagu-
lants: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed:
American College of Chest Physicians Evidence-Based Clinical Practice
Guidelines. Chest. 2012;141(2, Suppl):e24S–43S. doi: http://dx.doi.org/
10.1378/chest.11-2291. PubMed.
60 Bijsterveld NR, Moons AH, Boekholdt SM, van Aken BE, Fennema H,
Peters RJ, et al. Ability of recombinant factor VIIa to reverse the antico-
agulant effect of the pentasaccharide fondaparinux in healthy volunteers.
Circulation. 2002;106(20):2550–4. doi: http://dx.doi.org/10.1161/
01.CIR.0000038501.87442.02. PubMed.
61 Bijsterveld NR, Vink R, van Aken BE, Fennema H, Peters RJ, Meijers
JC, et al. Recombinant factor VIIa reverses the anticoagulant effect of
the long-acting pentasaccharide idraparinux in healthy volunteers. Br J
Haematol. 2004;124(5):653–8. doi: http://dx.doi.org/10.1111/
j.1365-2141.2003.04811.x. PubMed.
62 Linkins LA, Warkentin TE, Pai M, Shivakumar S, Manji RA, Wells PS,
et al. Rivaroxaban for treatment of suspected or confirmed heparin-in-
duced thrombocytopenia study. J Thromb Haemost.
2016;14(6):1206–10. doi: http://dx.doi.org/10.1111/jth.13330. PubMed.
63 Sharifi M, Bay C, Vajo Z, Freeman W, Sharifi M, Schwartz F. New oral
anticoagulants in the treatment of heparin-induced thrombocytopenia.
Thromb Res. 2015;135(4):607–9. doi: http://dx.doi.org/10.1016/j.throm-
res.2015.01.009. PubMed.
64 Davis KA, Davis DO. Direct acting oral anticoagulants for the treatment
of suspected heparin-induced thrombocytopenia. Eur J Haematol.
2017;99(4):332–5. doi: http://dx.doi.org/10.1111/ejh.12921. PubMed.
65 Shatzel JJ, Crapster-Pregont M, Deloughery TG. Non-vitamin K antago-
nist oral anticoagulants for heparin-induced thrombocytopenia. A sys-
tematic review of 54 reported cases. Thromb Haemost.
2016;116(2):397–400. doi: http://dx.doi.org/10.1160/TH16-02-0101.
PubMed.
66 Barlow A, Barlow B, Reinaker T, Harris J. Potential Role of Direct Oral
Anticoagulants in the Management of Heparin-induced Thrombocytope-
nia. Pharmacotherapy. 2019;39(8):837–53. doi: http://dx.doi.org/
10.1002/phar.2298. PubMed.
67 Rogers KC, Finks SW. A New Option for Reversing the Anticoagulant
Effect of Factor Xa Inhibitors: Andexanet Alfa (ANDEXXA). Am J
Med. 2019;132(1):38–41. doi: http://dx.doi.org/10.1016/
j.amjmed.2018.06.028. PubMed.
68 Information for healthcare professionals for Ondexxyan http://www.on-
dexxya.eu/downloads/pdf/anx_144471_en.pdf.
69 Ollier E, Hodin S, Lanoiselée J, Escal J, Accassat S, De Magalhaes E, et
al. Effect of Activated Charcoal on Rivaroxaban Complex Absorption.
Clin Pharmacokinet. 2017;56(7):793–801. doi: http://dx.doi.org/
10.1007/s40262-016-0485-1. PubMed.
70 Kubitza D, Becka M, Roth A, Mueck W. Dose-escalation study of the
pharmacokinetics and pharmacodynamics of rivaroxaban in healthy el-
derly subjects. Curr Med Res Opin. 2008;24(10):2757–65. doi:
http://dx.doi.org/10.1185/03007990802361499. PubMed.
71 Sauter TC, Eberle B, Wuillemin WA, Thiele T, Angelillo-Scherrer A,
Exadaktylos AK, et al. How I manage patients with anticoagulation-as-
sociated bleeding or urgent surgery. Swiss Med Wkly. 2018;148:. doi:
http://dx.doi.org/10.4414/smw.2018.14598. PubMed.
72 Majeed A, Ågren A, Holmström M, Bruzelius M, Chaireti R, Odeberg J,
et al. Management of rivaroxaban- or apixaban-associated major bleed-
ing with prothrombin complex concentrates: a cohort study. Blood.
2017;130(15):1706–12. doi: http://dx.doi.org/10.1182/
blood-2017-05-782060. PubMed.
Review article: Medical guidelines Swiss Med Wkly. 2020;150:w20210
Swiss Medical Weekly · PDF of the online version · www.smw.ch
Published under the copyright license “Attribution – Non-Commercial – No Derivatives 4.0”.
No commercial reuse without permission. See http://emh.ch/en/services/permissions.html.
Page 13 of 14
73 Joseph J, Rabbolini D, Enjeti AK, Favaloro E, Kopp MC, McRae S, et
al. Diagnosis and management of heparin-induced thrombocytopenia: a
consensus statement from the Thrombosis and Haemostasis Society of
Australia and New Zealand HIT Writing Group. Med J Aust.
2019;210(11):509–16. doi: http://dx.doi.org/10.5694/mja2.50213.
PubMed.
74 Chong BH, Magnani HN. Danaparoid for the treatment of heparin-in-
duced thrombocytopenia. In: Warkentin TE, Greinacher A, editors. He-
parin-induced thrombocytopenia. 4th edition. London, UK: Informa
Healthcare; 2007.
75 Fischer KG. Hemodialysis in heparin-induced thrombocytopenia. In:
Warkentin TE, Greinacher A, editors. Heparin-induced thrombocytope-
nia. 4th edition. London, UK: Informa Healthcare; 2007. p. 463–85.
76 Tang IY, Cox DS, Patel K, Reddy BV, Nahlik L, Trevino S, et al. Arga-
troban and renal replacement therapy in patients with heparin-induced
thrombocytopenia. Ann Pharmacother. 2005;39(2):231–6. doi:
http://dx.doi.org/10.1345/aph.1E480. PubMed.
77 Lewis BE, Hursting MJ. Argatroban therapy in heparin-induced throm-
bocytopenia. In: Warkentin TE, Greinacher A, editors. Heparin-induced
thrombocytopenia. 4th edition. Boca Raton, Florida: CRC Press; 2007.
p. 379–408.
78 Jang IK, Lewis BE, Matthai WH, Jr, Kleiman NS. Argatroban anticoag-
ulation in conjunction with glycoprotein IIb/IIIa inhibition in patients
undergoing percutaneous coronary intervention: an open-label, nonran-
domized pilot study. J Thromb Thrombolysis. 2004;18(1):31–7. doi:
http://dx.doi.org/10.1007/s11239-004-0171-2. PubMed.
79 Lewis BE, Matthai WH, Jr, Cohen M, Moses JW, Hursting MJ, Leya F;
ARG-216/310/311 Study Investigators. Argatroban anticoagulation dur-
ing percutaneous coronary intervention in patients with heparin-induced
thrombocytopenia. Catheter Cardiovasc Interv. 2002;57(2):177–84. doi:
http://dx.doi.org/10.1002/ccd.10276. PubMed.
80 Selleng K, Warkentin TE, Greinacher A. Heparin-induced thrombocy-
topenia in intensive care patients. Crit Care Med. 2007;35(4):1165–76.
doi: http://dx.doi.org/10.1097/01.CCM.0000259538.02375.A5.
PubMed.
81 Beiderlinden M, Treschan T, Görlinger K, Peters J. Argatroban in extra-
corporeal membrane oxygenation. Artif Organs. 2007;31(6):461–5. doi:
http://dx.doi.org/10.1111/j.1525-1594.2007.00388.x. PubMed.
82 Kleinschmidt S, Stephan B, Pindur G, Bauer C. Argatroban: Pharmakol-
ogische Eigenschaften und anästhesiologische Aspekte [Argatroban:
pharmacological properties and anaesthesiological aspects]. Anaesthe-
sist. 2006;55(4):443–50. doi: http://dx.doi.org/10.1007/
s00101-005-0962-7. PubMed.
83 Koster A, Spiess B, Jurmann M, Dyke CM, Smedira NG, Aronson S, et
al. Bivalirudin provides rapid, effective, and reliable anticoagulation
during off-pump coronary revascularization: results of the “EVOLU-
TION OFF” trial. Anesth Analg. 2006;103(3):540–4. doi:
http://dx.doi.org/10.1213/01.ane.0000226098.95698.0f. PubMed.
84 Spiess BD. Update on heparin-induced thrombocytopenia and cardio-
vascular interventions. Semin Hematol. 2005;42(3, Suppl 3):S22–7. doi:
http://dx.doi.org/10.1053/j.seminhematol.2005.05.014. PubMed.
85 Spiess BD, DeAnda A, McCarthy HL, Yeatman D, Katlaps G, Cooper
C, et al. Case 1-2006: off-pump coronary artery bypass graft surgery an-
ticoagulation with bivalirudin: a patient with heparin-induced thrombo-
cytopenia syndrome type II and renal failure. J Cardiothorac Vasc
Anesth. 2006;20(1):106–11. doi: http://dx.doi.org/10.1053/j.jv-
ca.2005.11.011. PubMed.
86 Koster A, Dyke CM, Aldea G, Smedira NG, McCarthy HL, 2nd, Aron-
son S, et al. Bivalirudin during cardiopulmonary bypass in patients with
previous or acute heparin-induced thrombocytopenia and heparin anti-
bodies: results of the CHOOSE-ON trial. Ann Thorac Surg.
2007;83(2):572–7. doi: http://dx.doi.org/10.1016/j.athorac-
sur.2006.09.038. PubMed.
87 Vasquez JC, Vichiendilokkul A, Mahmood S, Baciewicz FA, Jr. Antico-
agulation with bivalirudin during cardiopulmonary bypass in cardiac
surgery. Ann Thorac Surg. 2002;74(6):2177–9. doi: http://dx.doi.org/
10.1016/S0003-4975(02)04125-5. PubMed.
Review article: Medical guidelines Swiss Med Wkly. 2020;150:w20210
Swiss Medical Weekly · PDF of the online version · www.smw.ch
Published under the copyright license “Attribution – Non-Commercial – No Derivatives 4.0”.
No commercial reuse without permission. See http://emh.ch/en/services/permissions.html.
Page 14 of 14
